Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors

Background Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increased risk for treatment toxicity and adverse neurocognitive out...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuro-oncology Vol. 165; no. 1; pp. 161 - 169
Main Authors Grob, Sydney T., Miller, Kristen R., Sanford, Bridget, Donson, Andrew M., Jones, Kenneth, Griesinger, Andrea M., Amani, Vladimir, Foreman, Nicholas K., Liu, Arthur, Handler, Michael, Hankinson, Todd C., Milgrom, Sarah, Levy, Jean M. Mulcahy
Format Journal Article
LanguageEnglish
Published New York Springer US 01.10.2023
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0167-594X
1573-7373
1573-7373
DOI10.1007/s11060-023-04472-7

Cover

Loading…
Abstract Background Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increased risk for treatment toxicity and adverse neurocognitive outcomes. Materials The Human 660W-Quad v1.0 DNA BeadChip analysis (Illumina) was used to evaluate 1048 SNPs from 59 DNA repair genes in 46 subjects. IQ testing was measured by the Wechsler Intelligence Scale for Children. Linear regression was used to identify the 10 SNPs with the strongest association with IQ scores while adjusting for radiation type. Results The low vs high IQ patient cohorts were well matched for time from first treatment to most recent IQ, first treatment age, sex, and treatments received. 5 SNPs on 3 different genes ( CYP29, XRCC1 , and BRCA1 ) and on 3 different chromosomes (10, 19, and 17) had the strongest association with most recent IQ score that was not modified by radiation type. Furthermore, 5 SNPs on 4 different genes ( WRN, NR3C1, ERCC4, RAD51L1 ) on 4 different chromosomes (8, 5, 16, 14) had the strongest association with change in IQ independent of radiation type, first IQ, and years between IQ measures. Conclusions SNPs offer the potential to predict adverse neurocognitive outcomes in pediatric brain tumor survivors. Our results require validation in a larger patient cohort. Improving the ability to identify children at risk of treatment related neurocognitive deficits could allow for better treatment stratification and early cognitive interventions.
AbstractList Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increased risk for treatment toxicity and adverse neurocognitive outcomes.BACKGROUNDNeurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increased risk for treatment toxicity and adverse neurocognitive outcomes.The Human 660W-Quad v1.0 DNA BeadChip analysis (Illumina) was used to evaluate 1048 SNPs from 59 DNA repair genes in 46 subjects. IQ testing was measured by the Wechsler Intelligence Scale for Children. Linear regression was used to identify the 10 SNPs with the strongest association with IQ scores while adjusting for radiation type.MATERIALSThe Human 660W-Quad v1.0 DNA BeadChip analysis (Illumina) was used to evaluate 1048 SNPs from 59 DNA repair genes in 46 subjects. IQ testing was measured by the Wechsler Intelligence Scale for Children. Linear regression was used to identify the 10 SNPs with the strongest association with IQ scores while adjusting for radiation type.The low vs high IQ patient cohorts were well matched for time from first treatment to most recent IQ, first treatment age, sex, and treatments received. 5 SNPs on 3 different genes (CYP29, XRCC1, and BRCA1) and on 3 different chromosomes (10, 19, and 17) had the strongest association with most recent IQ score that was not modified by radiation type. Furthermore, 5 SNPs on 4 different genes (WRN, NR3C1, ERCC4, RAD51L1) on 4 different chromosomes (8, 5, 16, 14) had the strongest association with change in IQ independent of radiation type, first IQ, and years between IQ measures.RESULTSThe low vs high IQ patient cohorts were well matched for time from first treatment to most recent IQ, first treatment age, sex, and treatments received. 5 SNPs on 3 different genes (CYP29, XRCC1, and BRCA1) and on 3 different chromosomes (10, 19, and 17) had the strongest association with most recent IQ score that was not modified by radiation type. Furthermore, 5 SNPs on 4 different genes (WRN, NR3C1, ERCC4, RAD51L1) on 4 different chromosomes (8, 5, 16, 14) had the strongest association with change in IQ independent of radiation type, first IQ, and years between IQ measures.SNPs offer the potential to predict adverse neurocognitive outcomes in pediatric brain tumor survivors. Our results require validation in a larger patient cohort. Improving the ability to identify children at risk of treatment related neurocognitive deficits could allow for better treatment stratification and early cognitive interventions.CONCLUSIONSSNPs offer the potential to predict adverse neurocognitive outcomes in pediatric brain tumor survivors. Our results require validation in a larger patient cohort. Improving the ability to identify children at risk of treatment related neurocognitive deficits could allow for better treatment stratification and early cognitive interventions.
Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increased risk for treatment toxicity and adverse neurocognitive outcomes. The Human 660W-Quad v1.0 DNA BeadChip analysis (Illumina) was used to evaluate 1048 SNPs from 59 DNA repair genes in 46 subjects. IQ testing was measured by the Wechsler Intelligence Scale for Children. Linear regression was used to identify the 10 SNPs with the strongest association with IQ scores while adjusting for radiation type. The low vs high IQ patient cohorts were well matched for time from first treatment to most recent IQ, first treatment age, sex, and treatments received. 5 SNPs on 3 different genes (CYP29, XRCC1, and BRCA1) and on 3 different chromosomes (10, 19, and 17) had the strongest association with most recent IQ score that was not modified by radiation type. Furthermore, 5 SNPs on 4 different genes (WRN, NR3C1, ERCC4, RAD51L1) on 4 different chromosomes (8, 5, 16, 14) had the strongest association with change in IQ independent of radiation type, first IQ, and years between IQ measures. SNPs offer the potential to predict adverse neurocognitive outcomes in pediatric brain tumor survivors. Our results require validation in a larger patient cohort. Improving the ability to identify children at risk of treatment related neurocognitive deficits could allow for better treatment stratification and early cognitive interventions.
Background Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increased risk for treatment toxicity and adverse neurocognitive outcomes. Materials The Human 660W-Quad v1.0 DNA BeadChip analysis (Illumina) was used to evaluate 1048 SNPs from 59 DNA repair genes in 46 subjects. IQ testing was measured by the Wechsler Intelligence Scale for Children. Linear regression was used to identify the 10 SNPs with the strongest association with IQ scores while adjusting for radiation type. Results The low vs high IQ patient cohorts were well matched for time from first treatment to most recent IQ, first treatment age, sex, and treatments received. 5 SNPs on 3 different genes ( CYP29, XRCC1 , and BRCA1 ) and on 3 different chromosomes (10, 19, and 17) had the strongest association with most recent IQ score that was not modified by radiation type. Furthermore, 5 SNPs on 4 different genes ( WRN, NR3C1, ERCC4, RAD51L1 ) on 4 different chromosomes (8, 5, 16, 14) had the strongest association with change in IQ independent of radiation type, first IQ, and years between IQ measures. Conclusions SNPs offer the potential to predict adverse neurocognitive outcomes in pediatric brain tumor survivors. Our results require validation in a larger patient cohort. Improving the ability to identify children at risk of treatment related neurocognitive deficits could allow for better treatment stratification and early cognitive interventions.
BackgroundNeurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increased risk for treatment toxicity and adverse neurocognitive outcomes.MaterialsThe Human 660W-Quad v1.0 DNA BeadChip analysis (Illumina) was used to evaluate 1048 SNPs from 59 DNA repair genes in 46 subjects. IQ testing was measured by the Wechsler Intelligence Scale for Children. Linear regression was used to identify the 10 SNPs with the strongest association with IQ scores while adjusting for radiation type.ResultsThe low vs high IQ patient cohorts were well matched for time from first treatment to most recent IQ, first treatment age, sex, and treatments received. 5 SNPs on 3 different genes (CYP29, XRCC1, and BRCA1) and on 3 different chromosomes (10, 19, and 17) had the strongest association with most recent IQ score that was not modified by radiation type. Furthermore, 5 SNPs on 4 different genes (WRN, NR3C1, ERCC4, RAD51L1) on 4 different chromosomes (8, 5, 16, 14) had the strongest association with change in IQ independent of radiation type, first IQ, and years between IQ measures.ConclusionsSNPs offer the potential to predict adverse neurocognitive outcomes in pediatric brain tumor survivors. Our results require validation in a larger patient cohort. Improving the ability to identify children at risk of treatment related neurocognitive deficits could allow for better treatment stratification and early cognitive interventions.
Author Griesinger, Andrea M.
Liu, Arthur
Jones, Kenneth
Levy, Jean M. Mulcahy
Milgrom, Sarah
Foreman, Nicholas K.
Grob, Sydney T.
Amani, Vladimir
Miller, Kristen R.
Handler, Michael
Donson, Andrew M.
Hankinson, Todd C.
Sanford, Bridget
Author_xml – sequence: 1
  givenname: Sydney T.
  surname: Grob
  fullname: Grob, Sydney T.
  organization: Department of Pediatrics, University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado
– sequence: 2
  givenname: Kristen R.
  surname: Miller
  fullname: Miller, Kristen R.
  organization: Department of Pediatrics, University of Colorado School of Medicine
– sequence: 3
  givenname: Bridget
  surname: Sanford
  fullname: Sanford, Bridget
  organization: Department of Pediatrics, University of Colorado School of Medicine
– sequence: 4
  givenname: Andrew M.
  surname: Donson
  fullname: Donson, Andrew M.
  organization: Department of Pediatrics, University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado
– sequence: 5
  givenname: Kenneth
  surname: Jones
  fullname: Jones, Kenneth
  organization: Department of Pediatrics, University of Colorado School of Medicine
– sequence: 6
  givenname: Andrea M.
  surname: Griesinger
  fullname: Griesinger, Andrea M.
  organization: Department of Pediatrics, University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado
– sequence: 7
  givenname: Vladimir
  surname: Amani
  fullname: Amani, Vladimir
  organization: Department of Pediatrics, University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado
– sequence: 8
  givenname: Nicholas K.
  surname: Foreman
  fullname: Foreman, Nicholas K.
  organization: Department of Pediatrics, University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado, Department of Neurosurgery, Children’s Hospital Colorado
– sequence: 9
  givenname: Arthur
  surname: Liu
  fullname: Liu, Arthur
  organization: Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado, Department of Radiation Oncology, University of Colorado Anschutz
– sequence: 10
  givenname: Michael
  surname: Handler
  fullname: Handler, Michael
  organization: Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado, Department of Neurosurgery, Children’s Hospital Colorado
– sequence: 11
  givenname: Todd C.
  surname: Hankinson
  fullname: Hankinson, Todd C.
  organization: Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado, Department of Neurosurgery, Children’s Hospital Colorado
– sequence: 12
  givenname: Sarah
  surname: Milgrom
  fullname: Milgrom, Sarah
  organization: Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado, Department of Radiation Oncology, University of Colorado Anschutz, Department of Pharmacology, University of Colorado School of Medicine
– sequence: 13
  givenname: Jean M. Mulcahy
  surname: Levy
  fullname: Levy, Jean M. Mulcahy
  email: Jean.MulcahyLevy@cuanschutz.edu
  organization: Department of Pediatrics, University of Colorado School of Medicine, Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado, Department of Pharmacology, University of Colorado School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37878192$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1LxDAQhoMoun78AQ9S8OKlOvlokx5FdBUELwreQptOJbJN1iRd8N8b3VXBg6cc5nkmw_vuk23nHRJyTOGcAsiLSCnUUALjJQghWSm3yIxWkpeSS75NZkBrWVaNeN4j-zG-AoCQnO6SPS6VVLRhM_I4R4fJmmIZsLcm-RALPxQOp-CNf3E22RUWfkrGjxgL64o4hZVdbbhlltoUst-FNg_TNObJIdkZ2kXEo817QJ5urh-vbsv7h_nd1eV9aQRtUlkjB9U31ORra9qLgYmKA8NaGMU7qDoqOiVE05l6qLBXCgfWNIoK3lLVt8APyNl67zL4twlj0qONBheL1qGfomZKUQmNqllGT_-gr34KLl_3SSmhckxVpk421NSN2OtlsGMb3vV3Xhlga8AEH2PA4QehoD9L0etSdC5Ff5WiZZbUH8nY1CbrXcqhLf5X-VqN-R_3guH37H-sDz8Qn-8
CitedBy_id crossref_primary_10_3390_cancers17060947
crossref_primary_10_1016_j_pediatrneurol_2024_08_014
Cites_doi 10.1186/s42238-020-00033-1
10.1093/narcan/zcac012
10.1002/pbc.23162
10.1038/nrc3691
10.1093/jpepsy/15.1.105
10.1016/j.jnci.2017.07.002
10.1097/MRR.0000000000000340
10.3322/caac.20006
10.4103/ijmpo.ijmpo_22_16
10.1007/978-1-0716-2573-6_13
10.1093/neuonc/noz094
10.1016/j.cancergen.2014.03.002
10.1200/JCO.2001.19.8.2302
10.1007/s12020-019-02016-6
10.1093/nop/npad049
10.1002/hbm.25441
10.18632/oncotarget.10295
10.1111/j.1467-7687.2010.01022.x
10.1016/j.radonc.2009.06.015
10.1128/MCB.21.8.2858-2866.2001
10.1227/01.NEU.0000064804.00766.62
10.1002/pbc.24649
10.1158/1078-0432.ccr-11-0761
10.1186/s12885-017-3933-x
10.1007/s12519-023-00726-6
10.1093/neuonc/noz092
10.1093/neuonc/now057
10.1002/pbc.24366
10.1016/0360-3016(90)90393-X
10.1016/j.jpeds.2010.09.060
10.1111/ped.13198
10.1186/1471-2164-10-297
10.1097/FPC.0000000000000281
10.1093/neuonc/nos123
10.1177/08830738050200020901
10.1007/s11910-003-0064-3
10.1016/j.jpeds.2007.05.047
10.1200/JCO.1998.16.5.1723
10.1002/pbc.23192
10.1146/annurev-genet-021920-092410
10.1093/neuonc/noad072
10.1215/15228517-2008-089
10.1002/cam4.516
10.1200/JCO.20.02730
10.1016/j.celrep.2020.108625
10.3390/ijms21093059
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s11060-023-04472-7
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest Public Health Database (NC LIVE)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: C6C
  name: (Open Access) Springer Nature eJournals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1573-7373
EndPage 169
ExternalDocumentID 37878192
10_1007_s11060_023_04472_7
Genre Journal Article
GrantInformation_xml – fundername: University of Colorado Shared Resources Cancer Center Support Grant
  grantid: P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934; P30CA046934
– fundername: The Morgan Adams Foundation
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
28-
29L
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67Z
6NX
78A
7X7
88E
8AO
8C1
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFJLC
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Y
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAK
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
RNS
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZXP
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7TK
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
PUEGO
7X8
ID FETCH-LOGICAL-c419t-6e308d91c37361d4f245302e64c83b05b14b8449bc6f5ed88ef2998143a18da03
IEDL.DBID U2A
ISSN 0167-594X
1573-7373
IngestDate Thu Jul 10 23:04:23 EDT 2025
Sat Aug 23 12:31:40 EDT 2025
Mon Jul 21 05:57:16 EDT 2025
Tue Jul 01 02:14:17 EDT 2025
Thu Apr 24 23:02:41 EDT 2025
Fri Feb 21 02:42:01 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Neurocognitive outcome
Pediatric brain tumor
Single nucleotide polymorphism (SNP)
Language English
License 2023. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c419t-6e308d91c37361d4f245302e64c83b05b14b8449bc6f5ed88ef2998143a18da03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://link.springer.com/10.1007/s11060-023-04472-7
PMID 37878192
PQID 2888485945
PQPubID 37423
PageCount 9
ParticipantIDs proquest_miscellaneous_2881709862
proquest_journals_2888485945
pubmed_primary_37878192
crossref_primary_10_1007_s11060_023_04472_7
crossref_citationtrail_10_1007_s11060_023_04472_7
springer_journals_10_1007_s11060_023_04472_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20231000
PublicationDateYYYYMMDD 2023-10-01
PublicationDate_xml – month: 10
  year: 2023
  text: 20231000
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationTitle Journal of neuro-oncology
PublicationTitleAbbrev J Neurooncol
PublicationTitleAlternate J Neurooncol
PublicationYear 2023
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Institute NC (2020) Surveillance, Epidemiology and End Results Program. https://seer.cancer.gov/statfacts/html/childbrain.html
LohaugenGCAntonsenIHabergAGramstadAVikTBrubakkAMSkranesJComputerized working memory training improves function in adolescents born at extremely low birth weightJ Pediatr2011158555–56110.1016/j.jpeds.2010.09.060
BenzingVEggenbergerNSpitzhuttlJSiegwartVPastore-WappMKieferCSlavovaNGrotzerMHeinksTSchmidtMConzelmannASteinlinMEvertsRLeibundgutKThe Brainfit study: efficacy of cognitive training and exergaming in pediatric cancer survivors - a randomized controlled trialBMC Cancer2018181810.1186/s12885-017-3933-x292986785753470
MascelliSNozzaPJonesDTColinCPistorioAMilanaccioCRavegnaniMConsalesAWittOMoranaGCamaACapraVBiassoniRPfisterSMFigarella-BrangerDGarreMLRasoATP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytomaOncotarget20167479184792610.18632/oncotarget.10295273741065216988
AlanSKaufmanSERCoalsonDLIntelligent testing with the WISC-V2016New YorkWiley237
TakataMSasakiMSTachiiriSFukushimaTSonodaESchildDThompsonLHTakedaSChromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogsMol Cell Biol200121285828661:CAS:528:DC%2BD3MXisVyhtr0%3D10.1128/MCB.21.8.2858-2866.20011128326486915
Carpentieri SC, Waber DP, Pomeroy SL, Scott RM, Goumnerova LC, Kieran MW, Billett AL, Tarbell NJ (2003) Neuropsychological functioning after surgery in children treated for brain tumor. Neurosurgery 52: 1348–1356 (discussion 1356–1347)
JalalSEarleyJNTurchiJJDNA repair: from genome maintenance to biomarker and therapeutic targetClin Cancer Res201117697369841:CAS:528:DC%2BC3MXhsVKht73F10.1158/1078-0432.ccr-11-0761219085783218201
BrownALLupoPJOkcuMFLauCCRednamSScheurerMESOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastomaCancer Med20154167916861:CAS:528:DC%2BC2MXhvFKjur%2FL10.1002/cam4.516264004604673994
BrownALSokPRaghubarKPLupoPJRichardMAMorrisonACYangJJStewartCFOkcuMFChintagumpalaMMGajjarAKahalleyLSConklinHScheurerMEGenetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumorsNeuro Oncol2023251698170810.1093/neuonc/noad07237038335
BledsoeJCBreigerDBreigerMShonkaSErmoianRPOjemannJGWernyDMLearySESGeyerJRDifferential trajectories of neurocognitive functioning in females versus males following treatment for pediatric brain tumorsNeuro Oncol201921131013181:CAS:528:DC%2BB3cXhvVCnurjK10.1093/neuonc/noz092311237536784260
MichalskiJMJanssAJVezinaLGSmithKSBillupsCABurgerPCEmbryLMCullenPLHardyKKPomeroySLBassJKPerkinsSMMerchantTEColtePDFitzgeraldTJBoothTNCherlowJMMuraszkoKMHadleyJKumarRHanYTarbellNJFouladiMPollackIFPackerRJLiYGajjarANorthcottPAChildren's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJ Clin Oncol202139268526971:CAS:528:DC%2BB38XjtVOrtLw%3D10.1200/JCO.20.02730341109258376317
JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin20095922524910.3322/caac.2000619474385
FeldmanDKrishnanAVSwamiSGiovannucciEFeldmanBJThe role of vitamin D in reducing cancer risk and progressionNat Rev Cancer2014143423571:CAS:528:DC%2BC2cXls1Wrtr8%3D10.1038/nrc369124705652
Montour-ProulxIKuehnSMKeeneDLBarrowmanNJHsuEMatzingerMADunlapHHaltonJMCognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocolJ Child Neurol20052012913310.1177/0883073805020002090115794179
HowarthRAAdamsonAMAshfordJMMerchantTEOggRJSchulenbergSEOggSLiJWuSXiongXConklinHMInvestigating the relationship between COMT polymorphisms and working memory performance among childhood brain tumor survivorsPediatr Blood Cancer201461404510.1002/pbc.2464923956130
AkelBSSahinSHuriMAkyuzCCognitive rehabilitation is advantageous in terms of fatigue and independence in pediatric cancer treatment: a randomized-controlled studyInt J Rehabil Res20194214515110.1097/MRR.000000000000034030741725
CorreaDDSatagopanJMartinABraunEKryza-LacombeMCheungKSharmaADimitriadoySO'ConnellKLeongSKarimiSLyoJDeAngelisLMOrlowIGenetic variants and cognitive functions in patients with brain tumorsNeuro Oncol201921129713091:CAS:528:DC%2BB3cXhvVCnu7jF10.1093/neuonc/noz094311237526784270
BrackettJKrullKRScheurerMELiuWSrivastavaDKStovallMMerchantTEPackerRJRobisonLLOkcuMFAntioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor StudyNeuro Oncol201210.1093/neuonc/nos123226615883408256
BergerNDBrownleePMChenMJMorrisonHOszKPloquinNPChanJAGoodarziAAHigh replication stress and limited Rad51-mediated DNA repair capacity, but not oxidative stress, underlie oligodendrocyte precursor cell radiosensitivityNAR Cancer202210.1093/narcan/zcac012354259019004414
PapastergiouJLiWSterlingCvan den BemtBPharmacogenetic-guided cannabis usage in the community pharmacy: evaluation of a pilot programJ Cannabis Res202022410.1186/s42238-020-00033-1335261067819344
Bergman NutleySSoderqvistSBrydeSThorellLBHumphreysKKlingbergTGains in fluid intelligence after training non-verbal reasoning in 4-year-old children: a controlled, randomized studyDev Sci20111459160110.1111/j.1467-7687.2010.01022.x21477197
CorreaDDSatagopanJCheungKAroraAKKryza-LacombeMXuYKarimiSLyoJDeAngelisLMOrlowICOMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumorsNeuro Oncol201618142514331:CAS:528:DC%2BC1cXptFGitA%3D%3D10.1093/neuonc/now057270916105035520
National Brain Tumor Society Brain Tumor Facts. https://braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/. Accessed 26 Sept 2023
MulhernRKKepnerJLThomasPRArmstrongFDFriedmanHSKunLENeuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group studyJ Clin Oncol199816172317281:STN:280:DyaK1c3ks1aqtA%3D%3D10.1200/JCO.1998.16.5.17239586884
CacabelosRPharmacogenomics of cognitive dysfunction and neuropsychiatric disorders in dementiaInt J Mol Sci202010.3390/ijms21093059323575287246738
KrullKRBrouwersPJainNZhangLBomgaarsLDreyerZMahoneyDBottomleySOkcuMFFolate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivorsJ Pediatr20081521011051:CAS:528:DC%2BD1cXhtFSisg%3D%3D10.1016/j.jpeds.2007.05.04718154909
Demir-LiraOEPradoJBoothJRNeurocognitive basis of deductive reasoning in children varies with parental educationHum Brain Mapp2021423396341010.1002/hbm.25441339782818249891
ThiesenSYinPJorgensenALZhangJEManzoVMcEvoyLBartonCPictonSBaileySBrockPVyasHWalkerDMakinGBandiSPizerBHawcuttDBPirmohamedMTPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicityPharmacogenet Genomics2017272132221:CAS:528:DC%2BC2sXntVGnsbo%3D10.1097/FPC.0000000000000281284451885432027
BarahmaniNCarpentieriSLiXNWangTCaoYHoweLKilburnLChintagumpalaMLauCOkcuMFGlutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastomaNeuro Oncol2009112923001:CAS:528:DC%2BD1MXotlSisLg%3D10.1215/15228517-2008-089189529802718973
PalmerSLGoloubevaOReddickWEGlassJOGajjarAKunLMerchantTEMulhernRKPatterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysisJ Clin Oncol200119230223081:STN:280:DC%2BD3M3mtFOgsw%3D%3D10.1200/JCO.2001.19.8.230211304784
CacabelosRNaidooVMartinez-IglesiasOCorzoLCacabelosNPegoRCarrilJCPharmacogenomics of Alzheimer's disease: novel strategies for drug utilization and developmentMethods Mol Biol202225472753871:CAS:528:DC%2BB3sXjs12jtLg%3D10.1007/978-1-0716-2573-6_1336068470
AndreassenCNAlsnerJGenetic variants and normal tissue toxicity after radiotherapy: a systematic reviewRadiother Oncol2009922993091:CAS:528:DC%2BD1MXhtFajt7fF10.1016/j.radonc.2009.06.01519683821
JannounLBloomHJLong-term psychological effects in children treated for intracranial tumorsInt J Radiat Oncol Biol Phys1990187477531:STN:280:DyaK3c3hs1egug%3D%3D10.1016/0360-3016(90)90393-X2323966
IshimaruSYuzaYKanekoTUrashimaMEffect of UGT2B17 deletion polymorphism on prognosis in pediatric cancerPediatr Int2017594274311:CAS:528:DC%2BC2sXlvFersb4%3D10.1111/ped.1319827805301
KamdarKYKrullKREl-ZeinRABrouwersPPotterBSHarrisLLHolmSDreyerZScagliaFEtzelCJBondyMOkcuMFFolate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapyPediatr Blood Cancer20115745446010.1002/pbc.23162216184103134130
RosserTLPackerRJNeurocognitive dysfunction in children with neurofibromatosis type 1Curr Neurol Neurosci Rep2003312913610.1007/s11910-003-0064-312583841
BonillaBHengelSRGrundyMKBernsteinKARAD51 gene family structure and functionAnnu Rev Genet20205425461:CAS:528:DC%2BB3cXhtlyitLvE10.1146/annurev-genet-021920-092410326630497703940
WangJOhYTLiZDouJTangSWangXWangHTakedaSWangYRAD52 adjusts repair of single-strand breaks via reducing DNA-damage-promoted XRCC1/LIG3alpha co-localizationCell Rep2021341:CAS:528:DC%2BB3MXhsVeqt7c%3D10.1016/j.celrep.2020.108625334401617872142
SepeDMMcWilliamsTChenJKershenbaumAZhaoHLaMDevidasMLangeBRebbeckTRAplencRGermline genetic variation and treatment response on CCG-1891Pediatr Blood Cancer20125869570010.1002/pbc.2319221618417
RednamSScheurerMEAdesinaALauCCOkcuMFGlutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastomaPediatr Blood Cancer2013605935981:CAS:528:DC%2BC2cXhslWhu7rE10.1002/pbc.2436623065688
BuneviciusALawsERSaudargieneATamasauskasAIervasiGDeltuvaVSmithTRBuneviciusRCommon genetic variations of deiodinase genes and prognosis of brain tumor patientsEndocrine2019665635721:CAS:528:DC%2BC1MXhs1CitbvP10.1007/s12020-019-02016-631452060
RothJJSantiMRorke-AdamsLBHardingBNBusseTMTookeLSBiegelJADiagnostic application of high resolution single nucleotide polymorphism array analysis for children w
A Lassaletta (4472_CR5) 2023; 19
M Takata (4472_CR40) 2001; 21
OE Demir-Lira (4472_CR13) 2021; 42
CN Andreassen (4472_CR17) 2009; 92
4472_CR3
JM Michalski (4472_CR46) 2021; 39
4472_CR6
DD Correa (4472_CR18) 2016; 18
R Cacabelos (4472_CR44) 2020
JC Bledsoe (4472_CR8) 2019; 21
AL Brown (4472_CR36) 2023; 25
R Cacabelos (4472_CR45) 2022; 2547
BS Akel (4472_CR49) 2019; 42
S Jalal (4472_CR14) 2011; 17
A Jemal (4472_CR2) 2009; 59
AL Brown (4472_CR26) 2015; 4
I Montour-Proulx (4472_CR38) 2005; 20
KR Krull (4472_CR23) 2008; 152
S Thiesen (4472_CR25) 2017; 27
J Brackett (4472_CR30) 2012
D Feldman (4472_CR33) 2014; 14
J Papastergiou (4472_CR43) 2020; 2
S Bergman Nutley (4472_CR47) 2011; 14
ND Berger (4472_CR42) 2022
A Abo-Bakr (4472_CR27) 2017; 29
A Bunevicius (4472_CR19) 2019; 66
DM Sepe (4472_CR21) 2012; 58
S Alan (4472_CR16) 2016
MV Hollegaard (4472_CR15) 2009; 10
B Bonilla (4472_CR39) 2020; 54
SL Palmer (4472_CR9) 2001; 19
V Benzing (4472_CR37) 2018; 18
DD Correa (4472_CR20) 2019; 21
RA Howarth (4472_CR31) 2014; 61
J Wang (4472_CR41) 2021; 34
JJ Roth (4472_CR34) 2014; 207
S Ishimaru (4472_CR24) 2017; 59
KY Kamdar (4472_CR22) 2011; 57
GC Lohaugen (4472_CR48) 2011; 158
S Rednam (4472_CR29) 2013; 60
S Mascelli (4472_CR35) 2016; 7
L Chang (4472_CR12) 2023
RK Mulhern (4472_CR4) 1998; 16
B Yilmaz (4472_CR32) 2017; 38
L Jannoun (4472_CR10) 1990; 18
4472_CR1
TL Rosser (4472_CR11) 2003; 3
DP Waber (4472_CR7) 1990; 15
N Barahmani (4472_CR28) 2009; 11
37609195 - Res Sq. 2023 Aug 07
References_xml – reference: JalalSEarleyJNTurchiJJDNA repair: from genome maintenance to biomarker and therapeutic targetClin Cancer Res201117697369841:CAS:528:DC%2BC3MXhsVKht73F10.1158/1078-0432.ccr-11-0761219085783218201
– reference: CorreaDDSatagopanJMartinABraunEKryza-LacombeMCheungKSharmaADimitriadoySO'ConnellKLeongSKarimiSLyoJDeAngelisLMOrlowIGenetic variants and cognitive functions in patients with brain tumorsNeuro Oncol201921129713091:CAS:528:DC%2BB3cXhvVCnu7jF10.1093/neuonc/noz094311237526784270
– reference: BarahmaniNCarpentieriSLiXNWangTCaoYHoweLKilburnLChintagumpalaMLauCOkcuMFGlutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastomaNeuro Oncol2009112923001:CAS:528:DC%2BD1MXotlSisLg%3D10.1215/15228517-2008-089189529802718973
– reference: FeldmanDKrishnanAVSwamiSGiovannucciEFeldmanBJThe role of vitamin D in reducing cancer risk and progressionNat Rev Cancer2014143423571:CAS:528:DC%2BC2cXls1Wrtr8%3D10.1038/nrc369124705652
– reference: WangJOhYTLiZDouJTangSWangXWangHTakedaSWangYRAD52 adjusts repair of single-strand breaks via reducing DNA-damage-promoted XRCC1/LIG3alpha co-localizationCell Rep2021341:CAS:528:DC%2BB3MXhsVeqt7c%3D10.1016/j.celrep.2020.108625334401617872142
– reference: BergerNDBrownleePMChenMJMorrisonHOszKPloquinNPChanJAGoodarziAAHigh replication stress and limited Rad51-mediated DNA repair capacity, but not oxidative stress, underlie oligodendrocyte precursor cell radiosensitivityNAR Cancer202210.1093/narcan/zcac012354259019004414
– reference: BledsoeJCBreigerDBreigerMShonkaSErmoianRPOjemannJGWernyDMLearySESGeyerJRDifferential trajectories of neurocognitive functioning in females versus males following treatment for pediatric brain tumorsNeuro Oncol201921131013181:CAS:528:DC%2BB3cXhvVCnurjK10.1093/neuonc/noz092311237536784260
– reference: ChangLPatelPPZhangYCohenACohenKJacobsonLLadraMPetersonRKAcharyaSImpact of socioeconomic status and chemotherapy on neurocognitive performance in children with brain tumorsNeuro-Oncol Pract202310.1093/nop/npad049
– reference: BonillaBHengelSRGrundyMKBernsteinKARAD51 gene family structure and functionAnnu Rev Genet20205425461:CAS:528:DC%2BB3cXhtlyitLvE10.1146/annurev-genet-021920-092410326630497703940
– reference: BuneviciusALawsERSaudargieneATamasauskasAIervasiGDeltuvaVSmithTRBuneviciusRCommon genetic variations of deiodinase genes and prognosis of brain tumor patientsEndocrine2019665635721:CAS:528:DC%2BC1MXhs1CitbvP10.1007/s12020-019-02016-631452060
– reference: BenzingVEggenbergerNSpitzhuttlJSiegwartVPastore-WappMKieferCSlavovaNGrotzerMHeinksTSchmidtMConzelmannASteinlinMEvertsRLeibundgutKThe Brainfit study: efficacy of cognitive training and exergaming in pediatric cancer survivors - a randomized controlled trialBMC Cancer2018181810.1186/s12885-017-3933-x292986785753470
– reference: Bergman NutleySSoderqvistSBrydeSThorellLBHumphreysKKlingbergTGains in fluid intelligence after training non-verbal reasoning in 4-year-old children: a controlled, randomized studyDev Sci20111459160110.1111/j.1467-7687.2010.01022.x21477197
– reference: Institute NC (2020) Surveillance, Epidemiology and End Results Program. https://seer.cancer.gov/statfacts/html/childbrain.html
– reference: LassalettaAMoralesJSValenzuelaPLEstesoBKahalleyLSMabbottDJUnnikrishnanSPanizoECalvoFNeurocognitive outcomes in pediatric brain tumors after treatment with proton versus photon radiation: a systematic review and meta-analysisWorld J Pediatr20231972774010.1007/s12519-023-00726-63715486110348930
– reference: LohaugenGCAntonsenIHabergAGramstadAVikTBrubakkAMSkranesJComputerized working memory training improves function in adolescents born at extremely low birth weightJ Pediatr2011158555–56110.1016/j.jpeds.2010.09.060
– reference: National Brain Tumor Society Brain Tumor Facts. https://braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/. Accessed 26 Sept 2023
– reference: Abo-BakrAMossallamGEl AzharyNHafezHBadawyRImpact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemiaJ Egypt Natl Canc Inst20172912713310.1016/j.jnci.2017.07.00228844589
– reference: PapastergiouJLiWSterlingCvan den BemtBPharmacogenetic-guided cannabis usage in the community pharmacy: evaluation of a pilot programJ Cannabis Res202022410.1186/s42238-020-00033-1335261067819344
– reference: AlanSKaufmanSERCoalsonDLIntelligent testing with the WISC-V2016New YorkWiley237
– reference: HowarthRAAdamsonAMAshfordJMMerchantTEOggRJSchulenbergSEOggSLiJWuSXiongXConklinHMInvestigating the relationship between COMT polymorphisms and working memory performance among childhood brain tumor survivorsPediatr Blood Cancer201461404510.1002/pbc.2464923956130
– reference: MascelliSNozzaPJonesDTColinCPistorioAMilanaccioCRavegnaniMConsalesAWittOMoranaGCamaACapraVBiassoniRPfisterSMFigarella-BrangerDGarreMLRasoATP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytomaOncotarget20167479184792610.18632/oncotarget.10295273741065216988
– reference: MichalskiJMJanssAJVezinaLGSmithKSBillupsCABurgerPCEmbryLMCullenPLHardyKKPomeroySLBassJKPerkinsSMMerchantTEColtePDFitzgeraldTJBoothTNCherlowJMMuraszkoKMHadleyJKumarRHanYTarbellNJFouladiMPollackIFPackerRJLiYGajjarANorthcottPAChildren's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJ Clin Oncol202139268526971:CAS:528:DC%2BB38XjtVOrtLw%3D10.1200/JCO.20.02730341109258376317
– reference: KamdarKYKrullKREl-ZeinRABrouwersPPotterBSHarrisLLHolmSDreyerZScagliaFEtzelCJBondyMOkcuMFFolate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapyPediatr Blood Cancer20115745446010.1002/pbc.23162216184103134130
– reference: TakataMSasakiMSTachiiriSFukushimaTSonodaESchildDThompsonLHTakedaSChromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogsMol Cell Biol200121285828661:CAS:528:DC%2BD3MXisVyhtr0%3D10.1128/MCB.21.8.2858-2866.20011128326486915
– reference: PalmerSLGoloubevaOReddickWEGlassJOGajjarAKunLMerchantTEMulhernRKPatterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysisJ Clin Oncol200119230223081:STN:280:DC%2BD3M3mtFOgsw%3D%3D10.1200/JCO.2001.19.8.230211304784
– reference: SepeDMMcWilliamsTChenJKershenbaumAZhaoHLaMDevidasMLangeBRebbeckTRAplencRGermline genetic variation and treatment response on CCG-1891Pediatr Blood Cancer20125869570010.1002/pbc.2319221618417
– reference: Carpentieri SC, Waber DP, Pomeroy SL, Scott RM, Goumnerova LC, Kieran MW, Billett AL, Tarbell NJ (2003) Neuropsychological functioning after surgery in children treated for brain tumor. Neurosurgery 52: 1348–1356 (discussion 1356–1347)
– reference: AkelBSSahinSHuriMAkyuzCCognitive rehabilitation is advantageous in terms of fatigue and independence in pediatric cancer treatment: a randomized-controlled studyInt J Rehabil Res20194214515110.1097/MRR.000000000000034030741725
– reference: CorreaDDSatagopanJCheungKAroraAKKryza-LacombeMXuYKarimiSLyoJDeAngelisLMOrlowICOMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumorsNeuro Oncol201618142514331:CAS:528:DC%2BC1cXptFGitA%3D%3D10.1093/neuonc/now057270916105035520
– reference: RothJJSantiMRorke-AdamsLBHardingBNBusseTMTookeLSBiegelJADiagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumorsCancer Genet20142071111231:CAS:528:DC%2BC2cXms1GjtLc%3D10.1016/j.cancergen.2014.03.002247677144161453
– reference: CacabelosRNaidooVMartinez-IglesiasOCorzoLCacabelosNPegoRCarrilJCPharmacogenomics of Alzheimer's disease: novel strategies for drug utilization and developmentMethods Mol Biol202225472753871:CAS:528:DC%2BB3sXjs12jtLg%3D10.1007/978-1-0716-2573-6_1336068470
– reference: HollegaardMVGrauholmJBorglumANyegaardMNorgaard-PedersenBOrntoftTMortensenPBWiufCMorsODidriksenMThorsenPHougaardDMGenome-wide scans using archived neonatal dried blood spot samplesBMC Genomics2009102971:CAS:528:DC%2BD1MXosVKmtL0%3D10.1186/1471-2164-10-297195758122713266
– reference: AndreassenCNAlsnerJGenetic variants and normal tissue toxicity after radiotherapy: a systematic reviewRadiother Oncol2009922993091:CAS:528:DC%2BD1MXhtFajt7fF10.1016/j.radonc.2009.06.01519683821
– reference: BrownALSokPRaghubarKPLupoPJRichardMAMorrisonACYangJJStewartCFOkcuMFChintagumpalaMMGajjarAKahalleyLSConklinHScheurerMEGenetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumorsNeuro Oncol2023251698170810.1093/neuonc/noad07237038335
– reference: CacabelosRPharmacogenomics of cognitive dysfunction and neuropsychiatric disorders in dementiaInt J Mol Sci202010.3390/ijms21093059323575287246738
– reference: BrackettJKrullKRScheurerMELiuWSrivastavaDKStovallMMerchantTEPackerRJRobisonLLOkcuMFAntioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor StudyNeuro Oncol201210.1093/neuonc/nos123226615883408256
– reference: JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin20095922524910.3322/caac.2000619474385
– reference: MulhernRKKepnerJLThomasPRArmstrongFDFriedmanHSKunLENeuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group studyJ Clin Oncol199816172317281:STN:280:DyaK1c3ks1aqtA%3D%3D10.1200/JCO.1998.16.5.17239586884
– reference: JannounLBloomHJLong-term psychological effects in children treated for intracranial tumorsInt J Radiat Oncol Biol Phys1990187477531:STN:280:DyaK3c3hs1egug%3D%3D10.1016/0360-3016(90)90393-X2323966
– reference: WaberDPGioiaGPacciaJShermanBDinklageDSolleeNUrionDKTarbellNJSallanSESex differences in cognitive processing in children treated with CNS prophylaxis for acute lymphoblastic leukemiaJ Pediatr Psychol1990151051221:STN:280:DyaK3c3hvVGmsQ%3D%3D10.1093/jpepsy/15.1.1052324905
– reference: RosserTLPackerRJNeurocognitive dysfunction in children with neurofibromatosis type 1Curr Neurol Neurosci Rep2003312913610.1007/s11910-003-0064-312583841
– reference: Demir-LiraOEPradoJBoothJRNeurocognitive basis of deductive reasoning in children varies with parental educationHum Brain Mapp2021423396341010.1002/hbm.25441339782818249891
– reference: RednamSScheurerMEAdesinaALauCCOkcuMFGlutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastomaPediatr Blood Cancer2013605935981:CAS:528:DC%2BC2cXhslWhu7rE10.1002/pbc.2436623065688
– reference: Montour-ProulxIKuehnSMKeeneDLBarrowmanNJHsuEMatzingerMADunlapHHaltonJMCognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocolJ Child Neurol20052012913310.1177/0883073805020002090115794179
– reference: BrownALLupoPJOkcuMFLauCCRednamSScheurerMESOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastomaCancer Med20154167916861:CAS:528:DC%2BC2MXhvFKjur%2FL10.1002/cam4.516264004604673994
– reference: IshimaruSYuzaYKanekoTUrashimaMEffect of UGT2B17 deletion polymorphism on prognosis in pediatric cancerPediatr Int2017594274311:CAS:528:DC%2BC2sXlvFersb4%3D10.1111/ped.1319827805301
– reference: YilmazBTokucGAKocAYesilEInvestigation of vitamin D receptor gene polymorphism in pediatric patients with brain cancerIndian J Med Paediatr Oncol20173812813210.4103/ijmpo.ijmpo_22_16289003195582548
– reference: ThiesenSYinPJorgensenALZhangJEManzoVMcEvoyLBartonCPictonSBaileySBrockPVyasHWalkerDMakinGBandiSPizerBHawcuttDBPirmohamedMTPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicityPharmacogenet Genomics2017272132221:CAS:528:DC%2BC2sXntVGnsbo%3D10.1097/FPC.0000000000000281284451885432027
– reference: KrullKRBrouwersPJainNZhangLBomgaarsLDreyerZMahoneyDBottomleySOkcuMFFolate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivorsJ Pediatr20081521011051:CAS:528:DC%2BD1cXhtFSisg%3D%3D10.1016/j.jpeds.2007.05.04718154909
– volume: 2
  start-page: 24
  year: 2020
  ident: 4472_CR43
  publication-title: J Cannabis Res
  doi: 10.1186/s42238-020-00033-1
– year: 2022
  ident: 4472_CR42
  publication-title: NAR Cancer
  doi: 10.1093/narcan/zcac012
– volume: 57
  start-page: 454
  year: 2011
  ident: 4472_CR22
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.23162
– ident: 4472_CR1
– volume: 14
  start-page: 342
  year: 2014
  ident: 4472_CR33
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3691
– volume: 15
  start-page: 105
  year: 1990
  ident: 4472_CR7
  publication-title: J Pediatr Psychol
  doi: 10.1093/jpepsy/15.1.105
– volume: 29
  start-page: 127
  year: 2017
  ident: 4472_CR27
  publication-title: J Egypt Natl Canc Inst
  doi: 10.1016/j.jnci.2017.07.002
– volume: 42
  start-page: 145
  year: 2019
  ident: 4472_CR49
  publication-title: Int J Rehabil Res
  doi: 10.1097/MRR.0000000000000340
– volume: 59
  start-page: 225
  year: 2009
  ident: 4472_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20006
– volume: 38
  start-page: 128
  year: 2017
  ident: 4472_CR32
  publication-title: Indian J Med Paediatr Oncol
  doi: 10.4103/ijmpo.ijmpo_22_16
– volume: 2547
  start-page: 275
  year: 2022
  ident: 4472_CR45
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-0716-2573-6_13
– volume: 21
  start-page: 1297
  year: 2019
  ident: 4472_CR20
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noz094
– volume: 207
  start-page: 111
  year: 2014
  ident: 4472_CR34
  publication-title: Cancer Genet
  doi: 10.1016/j.cancergen.2014.03.002
– volume: 19
  start-page: 2302
  year: 2001
  ident: 4472_CR9
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2001.19.8.2302
– volume: 66
  start-page: 563
  year: 2019
  ident: 4472_CR19
  publication-title: Endocrine
  doi: 10.1007/s12020-019-02016-6
– year: 2023
  ident: 4472_CR12
  publication-title: Neuro-Oncol Pract
  doi: 10.1093/nop/npad049
– volume: 42
  start-page: 3396
  year: 2021
  ident: 4472_CR13
  publication-title: Hum Brain Mapp
  doi: 10.1002/hbm.25441
– volume: 7
  start-page: 47918
  year: 2016
  ident: 4472_CR35
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10295
– volume: 14
  start-page: 591
  year: 2011
  ident: 4472_CR47
  publication-title: Dev Sci
  doi: 10.1111/j.1467-7687.2010.01022.x
– volume: 92
  start-page: 299
  year: 2009
  ident: 4472_CR17
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2009.06.015
– volume: 21
  start-page: 2858
  year: 2001
  ident: 4472_CR40
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.21.8.2858-2866.2001
– ident: 4472_CR6
  doi: 10.1227/01.NEU.0000064804.00766.62
– volume: 61
  start-page: 40
  year: 2014
  ident: 4472_CR31
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.24649
– volume: 17
  start-page: 6973
  year: 2011
  ident: 4472_CR14
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.ccr-11-0761
– volume: 18
  start-page: 18
  year: 2018
  ident: 4472_CR37
  publication-title: BMC Cancer
  doi: 10.1186/s12885-017-3933-x
– volume: 19
  start-page: 727
  year: 2023
  ident: 4472_CR5
  publication-title: World J Pediatr
  doi: 10.1007/s12519-023-00726-6
– ident: 4472_CR3
– volume: 21
  start-page: 1310
  year: 2019
  ident: 4472_CR8
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noz092
– volume: 18
  start-page: 1425
  year: 2016
  ident: 4472_CR18
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/now057
– volume: 60
  start-page: 593
  year: 2013
  ident: 4472_CR29
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.24366
– volume: 18
  start-page: 747
  year: 1990
  ident: 4472_CR10
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/0360-3016(90)90393-X
– volume: 158
  issue: 555–561
  year: 2011
  ident: 4472_CR48
  publication-title: J Pediatr
  doi: 10.1016/j.jpeds.2010.09.060
– start-page: 237
  volume-title: Intelligent testing with the WISC-V
  year: 2016
  ident: 4472_CR16
– volume: 59
  start-page: 427
  year: 2017
  ident: 4472_CR24
  publication-title: Pediatr Int
  doi: 10.1111/ped.13198
– volume: 10
  start-page: 297
  year: 2009
  ident: 4472_CR15
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-10-297
– volume: 27
  start-page: 213
  year: 2017
  ident: 4472_CR25
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000281
– year: 2012
  ident: 4472_CR30
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nos123
– volume: 20
  start-page: 129
  year: 2005
  ident: 4472_CR38
  publication-title: J Child Neurol
  doi: 10.1177/08830738050200020901
– volume: 3
  start-page: 129
  year: 2003
  ident: 4472_CR11
  publication-title: Curr Neurol Neurosci Rep
  doi: 10.1007/s11910-003-0064-3
– volume: 152
  start-page: 101
  year: 2008
  ident: 4472_CR23
  publication-title: J Pediatr
  doi: 10.1016/j.jpeds.2007.05.047
– volume: 16
  start-page: 1723
  year: 1998
  ident: 4472_CR4
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1998.16.5.1723
– volume: 58
  start-page: 695
  year: 2012
  ident: 4472_CR21
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.23192
– volume: 54
  start-page: 25
  year: 2020
  ident: 4472_CR39
  publication-title: Annu Rev Genet
  doi: 10.1146/annurev-genet-021920-092410
– volume: 25
  start-page: 1698
  year: 2023
  ident: 4472_CR36
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noad072
– volume: 11
  start-page: 292
  year: 2009
  ident: 4472_CR28
  publication-title: Neuro Oncol
  doi: 10.1215/15228517-2008-089
– volume: 4
  start-page: 1679
  year: 2015
  ident: 4472_CR26
  publication-title: Cancer Med
  doi: 10.1002/cam4.516
– volume: 39
  start-page: 2685
  year: 2021
  ident: 4472_CR46
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.02730
– volume: 34
  year: 2021
  ident: 4472_CR41
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2020.108625
– year: 2020
  ident: 4472_CR44
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21093059
– reference: 37609195 - Res Sq. 2023 Aug 07;:
SSID ssj0004731
Score 2.4059856
Snippet Background Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes...
Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may...
BackgroundNeurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 161
SubjectTerms Brain cancer
Brain Neoplasms - complications
Brain Neoplasms - genetics
Brain Neoplasms - radiotherapy
Brain tumors
BRCA1 protein
Child
Children
Cognition
Cognitive ability
Cranial Irradiation - adverse effects
DNA repair
Humans
Intelligence
Intelligence Tests
Medicine
Medicine & Public Health
Neurology
Neuropsychological Tests
Oncology
Patients
Pediatrics
Radiation
Radiation therapy
Single-nucleotide polymorphism
Survivors
Toxicity
Tumors
X-ray Repair Cross Complementing Protein 1
XRCC1 protein
SummonAdditionalLinks – databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1RS90wFD44hbGXsTk3q04y2NsMS29Om-RpDFFE0CeF-1aaNIHB1l69rb9_J216L0Pma5O06TnJyUnOyfcBfA3CFdI3iqMLmqPxils0mpeoahVcXtcjxMbNbXl1j9fLYpkO3NYprXK2iaOhbjoXz8i_L2irhrowWPxYPfDIGhWjq4lC4xXsReiymNKllmp7L1IlPkIyBtRymS7NTFfnaC8kOK1YXCAq8jL_XZieeZvPIqXjAnT5Dt4mz5H9nFT9HnZ8uw-vb1Js_APcRQRpKmOrx_gssuiwLrARsHKTJMS6oaf_9Wv2q2XrgezEU6q3mjk7mI2sEawf_lDJAdxfXtydX_HEmcAd5qbnpZdCNyZ3UskybzAsMPIC-RKdllYUNkerEY11ZSh8o7UPtCBp8prqXDe1kB9ht-1afwhsPBxSQQtrAkrUNoRgpF6YshaBvKYM8llglUuA4pHX4ne1hUKOQq5IyNUo5Epl8G3TZjXBabxY-2TWQ5Wm1rraDoQMvmyKaVLESEfd-m4Y6-RKGNqtZfBp0t_mc5JMVESBy-BsVuj25f_vy9HLfTmGN5GIfkrzO4Hd_nHwn8ld6e3pOCb_ApkE43g
  priority: 102
  providerName: ProQuest
Title Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors
URI https://link.springer.com/article/10.1007/s11060-023-04472-7
https://www.ncbi.nlm.nih.gov/pubmed/37878192
https://www.proquest.com/docview/2888485945
https://www.proquest.com/docview/2881709862
Volume 165
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1di9swTOzuYOxl7Hu53YoHe9sMdq3E9mNb2h0bV8a4QvcU4sSGwS0t12S__-Q0aRm3DfYSQ6R8SbY-IksCeB9EmSpfaY5lMByt19yhNTxDXehQyqLoSmxcLbPLFX5ep-s-KWw37HYfQpKdpD4mu5H3IjjpGC4QNdmFJ3CWRt-dZvFqPDlmQ-q-CyGJgNTiuk-V-fM9fldH92zMe_HRTu0snsDj3l5kkz2Dn8IDXz-Dh1d9RPw5XMe60QRj29t4LvbOYZvAujKVh61BbNM29JF-x37UbNeSdPjV422HTh3MxV4RrGl_EuQFrBbz69kl7zsl8BKlbXjmlTCVlaXSKpMVhjHGbkA-w9IoJ1In0RlE68ospL4yxgdSQ4ZspUKaqhDqJZzWm9q_Btb9EtLBCGcDKjQuhGCVGdusEIFspQTkQLC87MuIx24WN_mxAHIkck5Ezjsi5zqBD4drtvsiGv_Evhj4kPcLapePyVNHQ-xME3h3ANNSiPGNovabtsORWljy0RJ4teff4XGKBFOs_ZbAx4Ghx5v__V3O_w_9DTyK7ej3m_0u4LS5bf1bMloaN4ITvdZ0NDM5grPJYjpdxvHT9y9zGqfz5ddvBJ1ls1E3m-8AAL3nZA
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcEG8CBYwEJ7Bw4klsHxDi0WpLuyuEttLe0jxsCQmSpZuA-FP8RsZ57ApV9NZr_Ig1Mx7PeDzzATx3ooilLRXHwmmOxiqeo9E8QZUpV4RZ1pXYmM2T6Ql-WsbLHfgz5sL4Z5WjTuwUdVkX_o78dUSuGurYYPx29YN71CgfXR0hNHqxOLK_f5HLtn5z-JH4-yKKDvYXH6Z8QBXgBYam4YmVQpcmLKSSSViii9Aj59gECy1zEech5hrR5EXiYltqbR2pbE12RRbqMhOS5r0CuyjJlZnA7vv9-ecv20xMNSAgkvqhtS6HNJ0-WY-8L8HpjOQCUZFd--9ReM6-PReb7Y68g5twY7BV2bteuG7Bjq1uw9XZEI2_Awtfs5ra2OrMf_O4Pax2rCuRuXmWxOq2IQrbNftasXVLmunn0G81ooSw3ONUsKb9Ti134eRS6HkPJlVd2QfAuuso5bTIjUOJOnfOGakjk2TCkZ0WQDgSLC2GEuYeSeNbui2-7ImcEpHTjsipCuDlZsyqL-BxYe-9kQ_psJnX6Vb0Ani2aaZt6GMrWWXrtusTKmHIPwzgfs-_ze8kKUVfdy6AVyNDt5P_fy0PL17LU7g2XcyO0-PD-dEjuB55weoeGe7BpDlr7WMylpr8ySChDE4ve1P8Bc-VIB4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcUMsztAUjwQmsOrET2weEEGXVUlpxaKW9hTixJSRIlm4C4q_x6xg7zq5QRW-9xk5izctjz-MDeOFYnXPbSCpqp6jQVlIjtKKFkJV0dVpVocXG6VlxdCE-zvP5BvyZamF8WuVkE4Ohbrra35EfZHhUEyrXIj9wMS3i8-Hs7eIH9QhSPtI6wWmMInJif__C49vyzfEh8vplls0-nL8_ohFhgNYi1T0tLGeq0WnNJS_SRrhMeBQdW4haccNykwqjhNCmLlxuG6WsQ_Ot0MeoUtVUjON3b8FtyfPU65icy3VNpoxYiGiIcNXzWLAzlu3hOYxR3C0pE0Kih_vvpnjF070SpQ2b32wb7kavlbwbxWwHNmx7D7ZOY1z-Ppz77tU4RhaX_plH8CGdI6FZ5ipBiXRDj7S2S_K1JcsBbdTPOG8x4YUQ4xErSD98x5EHcHEj1HwIm23X2sdAwsWUdIoZ7QQXyjjnNFeZLirm0GNLIJ0IVtaxmbnH1PhWrtsweyKXSOQyELmUCbxavbMYW3lcO3tv4kMZ1XpZroUwgeerYVRIH2WpWtsNYU4qmcaTYgKPRv6tfsfRPPoOdAm8nhi6_vj_1_Lk-rU8gy1UhfLT8dnJLtzJvFyFbMM92OwvB7uPXlNvngbxJPDlpvXhL27nIu4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+predictors+of+neurocognitive+outcomes+in+survivors+of+pediatric+brain+tumors&rft.jtitle=Journal+of+neuro-oncology&rft.au=Grob%2C+Sydney+T.&rft.au=Miller%2C+Kristen+R.&rft.au=Sanford%2C+Bridget&rft.au=Donson%2C+Andrew+M.&rft.date=2023-10-01&rft.pub=Springer+US&rft.issn=0167-594X&rft.eissn=1573-7373&rft.volume=165&rft.issue=1&rft.spage=161&rft.epage=169&rft_id=info:doi/10.1007%2Fs11060-023-04472-7&rft.externalDocID=10_1007_s11060_023_04472_7
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-594X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-594X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-594X&client=summon